$HUN

Huntsman Corporation's average stock price target was reduced from $11 to $10.94 by 16 analysts, with forecasts ranging from $9 to $15. This implies a 27% upside from the Oct. 16 closing price. The consensus rating remains 'Hold' among 19 analysts, with 4 'Buy', 13 'Hold', and 2 'Sell' ratings.

Wells Fargo reduced its price target for Huntsman (NYSE:HUN) to $9.00 from $11.00, citing weak construction demand and margin pressures. The stock trades at $8.84, below InvestingPro’s Fair Value of $10.58. Wells Fargo maintained its Q3 2026 EBITDA estimate at $115 million but lowered its 2026 and 2027 EBITDA estimates. Huntsman's Q2 2026 earnings beat expectations, but its stock declined due to leverage concerns.

Jefferies reduced its price target for Huntsman Corp. (NYSE:HUN) to $11 from $16, citing European challenges but maintaining a Buy rating. The stock trades at $8.57, with potential upside. Huntsman's Q3 outlook is supported by industrial activity, but Europe faces gas costs and soft demand. The company expects $400M in synergies from its Olin merger. Q2 2026 earnings beat expectations, with revenue at $1.66B and adjusted EPS at $0.20.

Analysts from Mizuho and Citi maintained Hold ratings on Huntsman (HUN) with $11.00 price targets. Exxon Mobil (XOM) received a Buy rating and $185.00 target from UBS, while Barclays also recommended Buy with a $177.00 target. HUN closed at $9.05, XOM at $158.71.

Huntsman and Olin told Brazil's CADE that their proposed transaction does not overlap in agricultural inputs, responding to a query from the authority. The query was prompted by the companies' broad business-activity classification.

Olin (OLN) and Huntsman (HUN) cleared a U.S. antitrust hurdle for their all-stock merger, expected to create a $12.5B chemicals company with $400M in cost synergies. The deal, targeting 1H 2027 completion, still needs regulatory approvals. OLN shares fell 32.2% and HUN dropped 8.6% over the past year.

Olin and Huntsman announced the expiration of the Hart-Scott-Rodino waiting period for their proposed merger. Huntsman, a global chemical manufacturer, reported 2025 revenues of approximately $6 billion. The merger's completion is subject to regulatory approvals and other conditions.

Olin (OLN) and Huntsman (HUN) announced the expiration of the HSR Act waiting period for their proposed merger, satisfying a key closing condition. Shareholders approved the transaction, but regulatory approvals are still required. Olin is a chemical and ammunition manufacturer, while Huntsman is a diversified chemical producer with 2025 revenues of $6 billion.

The article highlights three U.S. small-cap stocks with recent insider buying: Parke Bancorp (PBHC), Anika Therapeutics (ANIK), and Huntsman (HUN). Parke Bancorp reported Q2 2026 net income growth, while Anika Therapeutics raised earnings guidance. Huntsman's chairman made significant share purchases amid a merger with Olin Corporation. All three companies are noted for potential undervaluation.

Huntsman and Olin have filed a Form II application in India for their planned merger, citing negligible overlap in the Indian market for epoxy-related chemicals and ethyleneamines. The companies are seeking antitrust clearance from India's competition regulator.